

# Pascal Richette

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201791/publications.pdf>

Version: 2024-02-01

119  
papers

5,143  
citations

94433

37  
h-index

95266

68  
g-index

124  
all docs

124  
docs citations

124  
times ranked

5720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of hyperuricemia and gouty conditions. <i>Current Opinion in Rheumatology</i> , 2014, 26, 186-191.	4.3	336
2	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2018, 379, 2209-2219.	27.0	326
3	Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 748-755.	0.9	251
4	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38.	0.9	225
5	Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. <i>BMC Medicine</i> , 2017, 15, 123.	5.5	217
6	Emerging pharmaceutical therapies for osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 673-688.	8.0	211
7	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011, 78, 598-603.	1.6	204
8	Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 139-144.	0.9	204
9	Biologic agents in osteoarthritis: hopes and disappointments. <i>Nature Reviews Rheumatology</i> , 2013, 9, 400-410.	8.0	186
10	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661.	8.0	169
11	Revisiting comorbidities in gout: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 142-147.	0.9	144
12	Splint for Base-of-Thumb Osteoarthritis. <i>Annals of Internal Medicine</i> , 2009, 150, 661.	3.9	135
13	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.9	130
14	Causal Factors for Knee, Hip, and Hand Osteoarthritis: A Mendelian Randomization Study in the UK Biobank. <i>Arthritis and Rheumatology</i> , 2019, 71, 1634-1641.	5.6	109
15	Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Research and Therapy</i> , 2013, 15, R123.	3.5	103
16	Interaction of HIF1 $\alpha$ and $\beta$ -catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5453-5458.	7.1	94
17	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015, 82, 345-351.	1.6	92
18	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568.	8.0	74

#	ARTICLE	IF	CITATIONS
19	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
20	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
21	Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1 $\beta$ activation on macrophages. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1506-1514.	0.9	72
22	Prevalence of Gout in the Adult Population of France. <i>Arthritis Care and Research</i> , 2016, 68, 261-266.	3.4	70
23	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59
24	Investigational drugs for hyperuricemia, an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 437-444.	4.1	52
25	Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 349-355.	0.9	52
26	Failure to reach uric acid target of $\leq 0.36$ mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. <i>RMD Open</i> , 2019, 5, e001015.	3.8	49
27	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. <i>Joint Bone Spine</i> , 2020, 87, 395-404.	1.6	47
28	Ultrasonography in gout: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 499-504.	0.8	47
29	A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. <i>Kidney International</i> , 2021, 99, 218-226.	5.2	45
30	Prophylaxis for acute gout flares after initiation of urate-lowering therapy. <i>Rheumatology</i> , 2014, 53, 1920-1926.	1.9	44
31	Spinal involvement with calcium pyrophosphate deposition disease in an academic rheumatology center: A series of 37 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1113-1126.	3.4	44
32	2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. <i>Joint Bone Spine</i> , 2022, 89, 105344.	1.6	44
33	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 963-968.	1.9	42
34	Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. <i>Arthritis Care and Research</i> , 2016, 68, 1036-1042.	3.4	40
35	Current and future therapies for gout. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1201-1211.	1.8	39
36	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39

#	ARTICLE	IF	CITATIONS
37	An exploratory ultrasound study of early gout. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 816-21.	0.8	39
38	Colchicine for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2933-2938.	1.8	37
39	Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. <i>Joint Bone Spine</i> , 2017, 84, 595-598.	1.6	37
40	Uric acid and cognitive decline: a double-edge sword?. <i>Current Opinion in Rheumatology</i> , 2018, 30, 183-187.	4.3	37
41	Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 338-342.	3.2	36
42	Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 452-455.e5.	2.9	36
43	Colchicine in Gout: An Update. <i>Current Pharmaceutical Design</i> , 2018, 24, 684-689.	1.9	34
44	Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. <i>Rheumatology</i> , 2019, 58, 410-417.	1.9	30
45	Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 755-760.	1.6	29
46	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>Joint Bone Spine</i> , 2018, 85, 609-614.	1.6	29
47	Intra-articular injections of platelet-rich plasma in symptomatic knee osteoarthritis: a consensus statement from French-speaking experts. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2021, 29, 3195-3210.	4.2	26
48	Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. <i>Rheumatology</i> , 2014, 53, 1457-1464.	1.9	25
49	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
50	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis—Methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021, 88, 105171.	1.6	23
51	The role of febuxostat in gout. <i>Current Opinion in Rheumatology</i> , 2019, 31, 152-158.	4.3	21
52	Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e482-e490.	0.9	21
53	Purine-rich foods: an innocent bystander of gout attacks?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1435-1436.	0.9	18
54	Benefits of Polymerase Chain Reaction Combined With Culture for the Diagnosis of Bone and Joint Infections: A Prospective Test Performance Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz511.	0.9	18

#	ARTICLE	IF	CITATIONS
55	Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture. <i>Arthritis Research and Therapy</i> , 2018, 20, 78.	3.5	17
56	Evaluation of the performances of "typical" imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study. <i>RMD Open</i> , 2019, 5, e000918.	3.8	17
57	Renal medulla in severe gout: typical findings on ultrasonography and dual-energy CT study in two patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 433-434.	0.9	17
58	Chondrocalcinosis of the Knee and the Risk of Osteoarthritis Progression: Data From the Knee and Hip Osteoarthritis Long-term Assessment Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 726-732.	5.6	17
59	Association of Specific Comorbidities with Monosodium Urate Crystal Deposition in Urate-Lowering Therapy-Naive Gout Patients: A Cross-Sectional Dual-Energy Computed Tomography Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1295.	2.4	17
60	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.9	17
61	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. <i>Joint Bone Spine</i> , 2020, 87, 387-393.	1.6	17
62	Should prednisolone be first-line therapy for acute gout?. <i>Lancet, The</i> , 2008, 372, 1301.	13.7	16
63	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. <i>Joint Bone Spine</i> , 2020, 87, 647-651.	1.6	16
64	Pain in women with knee and/or hip osteoarthritis is related to systemic inflammation and to adipose tissue dysfunction: Cross-sectional results of the KHOALA cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 129-136.	3.4	16
65	International position paper on the appropriate use of uricosurics with the introduction of lesinurad. <i>Clinical Rheumatology</i> , 2018, 37, 3159-3165.	2.2	15
66	Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort. <i>RMD Open</i> , 2016, 2, e000230.	3.8	14
67	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	1.6	14
68	Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?. <i>Arthritis and Rheumatology</i> , 2022, 74, 1343-1351.	5.6	14
69	Novel uricosurics. <i>Rheumatology</i> , 2018, 57, i42-i46.	1.9	13
70	FAST: new look at the febuxostat safety profile. <i>Lancet, The</i> , 2020, 396, 1704-1705.	13.7	13
71	MRI and serum biomarkers correlate with radiographic features in painful hand osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 991-998.	0.8	13
72	Usefulness of taping in lower limb osteoarthritis. French clinical practice guidelines. <i>Joint Bone Spine</i> , 2008, 75, 475-478.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy. <i>Arthritis Care and Research</i> , 2018, 70, 918-924.	3.4	12
74	Treatment of Nongout Joint Deposition Diseases: An Update. <i>Arthritis</i> , 2014, 2014, 1-8.	2.0	11
75	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	3.4	11
76	Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1126-1128.	0.9	11
77	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 3257-3268.	1.9	11
78	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orenzia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	1.9	10
79	Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 60-65.	0.9	9
80	Critical appraisal of the role of pegloticase in the management of gout. <i>Open Access Rheumatology: Research and Reviews</i> , 2012, Volume 4, 63-70.	1.6	8
81	Computational Lexical Analysis of the Language Commonly Used to Describe Gout. <i>Arthritis Care and Research</i> , 2016, 68, 763-768.	3.4	8
82	Epidemiology of gout and hyperuricemia in New Caledonia. <i>Joint Bone Spine</i> , 2022, 89, 105286.	1.6	8
83	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. <i>RMD Open</i> , 2019, 5, e000914.	3.8	7
84	High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who's to Blame?. <i>Rheumatology and Therapy</i> , 2020, 7, 1011-1019.	2.3	7
85	Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. <i>RMD Open</i> , 2022, 8, e001986.	3.8	7
86	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	3.8	6
87	How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort. <i>Rheumatology</i> , 2022, 61, 2034-2042.	1.9	6
88	Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies. <i>Joint Bone Spine</i> , 2016, 83, 101-103.	1.6	5
89	Recommandations de la Société française de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uricémiant. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 332-341.	0.0	5
90	Inhibition of ADAMTS-5: the right target for osteoarthritis?. <i>Osteoarthritis and Cartilage</i> , 2022, 30, 175-177.	1.3	5

#	ARTICLE	IF	CITATIONS
91	Time to Total Knee Arthroplasty after Intra-Articular Hyaluronic Acid or Platelet-Rich Plasma Injections: A Systematic Literature Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3985.	2.4	5
92	Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 101-108.	2.3	4
93	Iterative percutaneous needle aponeurotomy for Dupuytren's disease: Functional outcome at 5-year follow-up. <i>Joint Bone Spine</i> , 2020, 87, 273-274.	1.6	4
94	MRI and ultrasonography for detection of early interphalangeal osteoarthritis. <i>Joint Bone Spine</i> , 2022, 89, 105370.	1.6	4
95	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
96	Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 20.	1.5	3
97	Response to: "Uric acid and incident dementia: a population-based cohort study" by Lee and Song. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e63-e63.	0.9	3
98	Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 761-774.	2.3	3
99	Metacarpophalangeal Joint Impairment in Hand Osteoarthritis and Its Association With Mechanical Factors: Results From the Digital Cohort Osteoarthritis Design Hand Osteoarthritis Cohort. <i>Arthritis Care and Research</i> , 2022, 74, 1696-1703.	3.4	3
100	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	2.3	3
101	Shoulder adhesive capsulitis: diagnostic value of active and passive range of motion with volume of gleno-humeral capsule as a reference. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 438-443.	2.2	3
102	Actualisation 2022 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2022, 89, 210-222.	0.0	3
103	Hyperferritinaemia and hyperuricaemia " a causal connection?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 628-629.	8.0	2
104	Defining remission in patients with gout. <i>Nature Reviews Rheumatology</i> , 2019, 15, 516-517.	8.0	2
105	Response to "Everything we see is a perspective, not the truth" by Chattopadhyay et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e46-e46.	0.9	2
106	Can gout management guidelines be solely evidence based?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 479-480.	8.0	2
107	Fat mass and response to TNF± blockers in early axial spondyloarthritis: an analysis of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 299-300.	0.9	2
108	The shrinking toe sign in gout. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151981.	3.4	2

#	ARTICLE	IF	CITATIONS
109	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1436-1444.	2.0	1
110	Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases. <i>Joint Bone Spine</i> , 2022, 89, 105253.	1.6	1
111	Eosinopenia to differentiate crystal-induced and septic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1201-1202.	0.9	1
112	Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey. <i>Rheumatology and Therapy</i> , 2022, 9, 823-838.	2.3	1
113	SAT0416â€¦ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUT PHASE 2 (USEFUL-2): DURATION OF FLARE PROPHYLAXIS. , 2019, , .		0
114	SAT0412â€¦DOES THERAPEUTIC EDUCATION IMPROVE GOUT MANAGEMENT: THE EXPERIENCE OF LARIBOISIÈRE UNIVERSITY HOSPITAL PARIS-FRANCE. , 2019, , .		0
115	OP0052â€¦FAILURE TO REACH SERUM URATE TARGET IS ASSOCIATED WITH ELEVATED MORTALITY IN GOUT. , 2019, , .		0
116	Impact du traitement par statines dans la progression radiologique de la gonarthrose: r�sultats issus de lâ€™analyse post-hoc de lâ€™essai SEKOIA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 81-86.	0.0	0
117	Traitements symptomatiques et locaux dans le rhumatisme psoriasique. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 307-309.	0.0	0
118	MRI Features Associated With the Detection of Microbial Pathogens by CT-Guided Biopsy in Septic Spondylodiscitis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e189-e194.	0.9	0
119	Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout management. <i>Lancet Rheumatology, The</i> , 2021, , .	3.9	0